Diverse Cell Death Signature Based Subtypes Predict the Prognosis and Immune Characteristics Within Glioma

Authors

  • Lin Wang Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Jia Song Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Jing Xu Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Yidan Qin Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Jia Li Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Yajuan Sun Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Hui Jin Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Jiajun Chen Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
  • Ziqian Wang Department of Neurosurgical Oncology, The First Hospital of Jilin University, Changchun, China

Keywords:

Cell Death , Glioma, DCD, immunotherapy

Abstract

Background. Cell death plays an essential role in the pathogenesis, progression, drug resistance and recurrence of glioma. Although multiple cell death pathways are involved in glioma development, there is lack of a stratification and prognostic modelling for glioma based on the integration of diverse genes for cell deaths.

Methods. In this study, 1254 diverse cell death (DCD)-related genes were assessed using the ConsensusClusterPlus assessment to identify DCD patterns in glioma. CIBERSORT, ssGSEA, and ESTIMATE algorithms were applied to evaluate immune microenvironment differences between subtypes. LASSO Cox regression was used to screen prognosis-related DCD genes, and a risk score model was constructed. TMB, TIDE, immune infiltration, and immunotherapy response was analyzed to evaluate the immune characteristics.

Results. Two DCD-related subgroups named Clusters 1 and 2, with distinct DCD levels, immune characteristics, and prognoses, were determined from glioma samples. A DCD-based risk score model was developed to assess DCD levels in glioma patients and divide patients into high- and low-risk groups. We found this risk model can be used as an independent prognostic factor for glioma patients. Notably, glioma patients with low risk scores exhibited subdued DCD activity, prolonged survival, and a favorable disposition towards benefiting from immune checkpoint blockade therapies.

Conclusions. This study established a novel signature classification and a risk model by comprehensively analyzing patterns of various DCDs to stratify glioma patients and to predict the prognosis and immune characteristics of glioma. We provided a theoretical basis for the clinical application of DCD-related genes in glioma prognosis and immunotherapy.

Published

2024-06-28

Issue

Section

Original Articles

How to Cite

Lin Wang, Jia Song, Jing Xu, Yidan Qin, Jia Li, Yajuan Sun, Hui Jin, Jiajun Chen, and Ziqian Wang , trans. 2024. “Diverse Cell Death Signature Based Subtypes Predict the Prognosis and Immune Characteristics Within Glioma”. Human Biology 94 (3): 665-75. https://humbiol.org/Home/article/view/81.